KOL Pulse AI· @KolPulseAI · X·· 20 小时前评分70
正文 · 原文
"Author concludes “modest” benefit; I would say “disappointing”." @DrSGraff
#ESMO26 TALENT: neoadjuvant T-DXd alone, with anastrozole or before TC in HR+/HER2-low early breast cancer. pCR 7%, 3% and 9%. Investigational. @DaiichiSankyoUS
https://hubs.ly/Q04CdhhS0
7 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：KOL Pulse AI · x.com